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ABSTRACT

FORMYLGLYCINAMIDE RIBONUCLEOTIDE AMIDOTRANSFERASE IN A REVERTANT OF A
CHINESE HAMSTER OVARY PURINE AUXOTROPH:
Implications for a mechanism of coordinate regulation of two enzymes
in the de novo biosynthesis of purines
Richard Louis Leff
1984
ABr, a revertant of the puri ne-requi ri ng Chinese hamster ovary cell
line Ade_P/\B, is examined.

A probably single mutational event is

responsible for Ade"PAB» and for its reversion (ABr).

Phosphoribosy1-

pyrophosphate ami dotransferase (PRPP ATase; EC 2.4.2.14) and fornylglycinamide ribonucleotide amidotransferase (FGAR ATase; EC 6.3.5.3) have
altered enzyme activities in Ade"PAB and ABr. Ade"PAB complements neithe
Ade"A (deficient in PRPP ATase) nor Ade~B (deficient in FGAR ATase).
Mixing studies results in no alterations of PRPP ATase and FGAR Atase
activities.

Structural changes in Ade~PAB and ABr have been described

which alter the apparent glutamine affinity of PRPP ATase.

In this

thesis, FGAR ATase in dialyzed enzyme extracts from ABr is found to
possess increased sensitivity to thermal inactivation at 50°C in
comparison to extracts from wild type (CHO).

Extracts from ABr and CHO

demonstrate equivalent FGAR ATase apparent affinity for glutamine, with
apparent binding constants (Km) of 0.54mM and 0.86mM, respectively.
Glutaminase sensitivity to thermal inactivation and apparent affinity for
glutamine is found to be equivalent in ABr and CHO.
Given the complementation pattern of Ade-PAB and the results of
mixing studies, the findings of structural alterations in both PRPP ATase
and FGAR ATase are discussed.

Various models within the confines of

established theory do not explain the properties of Ade~P/\B

and ABr.

Another possible model presented involves the separation of these two
enzymes from a single precursor.

However, the recent mapping of PRPP

ATase and FGAR ATase to different human chromosomes makes this theory
less likely.
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INTRODUCTION

The two enzymes of the purine de novo biosynthetic pathway classified
as amidotransferases are phosphoribosylpyrophosphate ami dotransferase
(PRPP ATase, EC 2.4.2.14) and formylglycinamide ribonucleotide
amidotransferase (FGAR ATase, EC 6.3.5.3).

As ami dotransferases, both

enzymes catalyze the formation of a carbon-nitrogen bond utilizing
t

glutamine as a nitrogen source.

Additionally, both enzymes possess

aminotransferase activity which substitutes ammonia for glutamine as the
nitrogen donor.

Chinese hamster ovary cell

(CH0-K1) mutants have been

isolated with altered PRPP ATase and FGAR ATase activities (1).

A brief

review of these two enzymes will be followed by a description of the
mutant CHO cell lines studied in this paper.
PRPP ATase catalyzes the formation of phosphoribosylamine (PRA) from
phosphoribosylpyrophosphate (PRPP) and glutamine (or ammonia)(2).

This

Glutamine _

or

Ammonia

a—Phosphoribosyl—

®

j}-Phosphoribosyl-

pyrophosphate

amine

(PP-ribose—P)

(PRA)

first committed step in the de novo synthesis of purines is a logical
focus for the regulation of the enzymatic pathway.

The complex

regulation of de novo purine synthesis involves many factors including
substrate availability, end product feedback inhibition, and enzyme
stability (2-13).

The recent purification of PRPP ATase from a human source (14) has
confirmed previous work on impure enzyme preparations.

PRPP ATase is

composed of 4-5 homogeneous subunits forming an active enzyme with a
molecular weight of 133,000 daltons (14-17).

The ami dotransferase and

ami notransferase activities copurify indicating that both activities are
contained in one enzyme (14).

The oxygen-sensitive and iron-sulfur

components of PRPP ATase are necessary for mammalian enzymatic activity
(18), but may not be directly involved with the active sites (19-21).
PRPP ATase possesses separate binding sites for the substrates glutamine
and PRPP, and for purine nucleotide feedback inhibitors (4,7,11,12,22).
FGAR ATase is the fourth enzyme in the de novo purine synthetic
pathway.

It catalyzes the formation of formylglycinamidine (FGAM) from

formyl glycinamide (FGAR) and glutamine (or ammonia) and the hydrolysis of

H

Glutamine
/

©
H

H,C^ "N>0/
H2C^ ^C=0
H /
|
H
C
C
XNH
l
HN^ VNH
P-5-R

ATP

Phosphonbosyl-

P-5 —R

Phosphoribosyl-

formylglycinamide tormylglycinanndin e
(FGAR)

ATP (2).

(FGAM)

FGAR ATase has been purified from avian liver as a single

polypeptide with a molecular weight of 133,000 daltons (23).
sites for the binding of glutamine and an FGAR-Mg+
characterized (24-28).

p

Separate

complex have been

FGAR ATase is not an iron-sulfur containing

enzyme (23) as is PRPP ATase from avian and mammalian sources (18).

In

vitro studies reveal that FGAR ATase ammonia-dependent activity is much
lower than its glutamine-dependent activity (24).

This differs
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from that found for PRPP ATase activity in vitro (1).
Several purine auxotrophic CHO cell lines, each deficient in an
enzyme of the de novo purine synthetic pathway, have been characterized
(29-33).

Recently, Oates, Vannais and Patterson (1) described an

interesting purine auxotroph.

This cell line (Ade_Pab) was found to

complement all the purine auxotrophic cell lines except those deficient
in either PRPP ATase (Ade~A) or FGAR ATase (Ade“B).
revealed a loss of measurable FGAR ATase activity.

Further analysis
Additionally, a

virtual loss of measurable glutamine-utilizing PRPP ATase activity with
an almost normal ammonia-utilizing PRPP ATase activity was identified.
Mixing studies on cell-free extracts from Ade_A, Ade"P/\B and CH0-K1
produced no changes in the level of the separate PRPP ATase activities.
Similarly, combinations of cell-free extracts fromAde"B, Ade“PAB and
CH0-K1 were not altered in the level of FGAR ATase activity (1).
Ade-P/\B cell lines were isolated from CH0-K1 using an ethyl methanesulphonate and BUdR-visible light procedure which usually produces point
mutations (34).

The alteration in both PRPP ATase and FGAR ATase in

Ade“PAB can be easily explained by theorizing two mutational events;
however, several properties of Ade_PAB argue against this possibility.
First, the frequency of isolation of Ade~PAB is approximately that for
either Ade“A or Ade"B.

If Ade“PAB was the result of two independent

events, then one would expect it to occur at a much lower rate than
either Ade~A or Ade"B.

Second, revertants of Ade'PAB (ABr) are not

infrequently isolated.

The final argument of Oates, Vannais and

Patterson is the lack of a viable complement between Ade~A (with normal
FGAR ATase) and Ade“PAB (with near normal ammonia-dependent PRPP ATase),
which should resemble ABr in PRPP ATase and FGAR ATase activities
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(described below).

These results are not easily explained in the context

of the enzyme levels of PRPP ATase and FGAR ATase for ABr.

Oates,

Vannais and Patterson (1) therefore conclude that this implies a more
complicated basis for Ade"P/\B Than two distinct mutational events.
ABr, isolated in more than 30 independent reversions of Ade_PAB (1)»
regains normal FGAR ATase activity, and retains near normal ammoniadependent PRPP ATase, while possessing only minimal glutamine-dependent
PRPP ATase activity.

Further investigation by Holmes (personal

communication) demonstrates the apparent decrease in (glutamine-dependent)
PRPP ATase activity in ABr as being the result of a decrease in apparent
affinity for glutamine.

Additionally, the virtual loss of

glutamine-dependent PRPP ATase activity in Ade-P/\B is due to a marked
decrease in apparent affinity for glutamine of several orders of
magnitude.

Ade_PAB does not appear to have altered apparent binding

constant for PRPP or molecular weight as judged by sucrose density
gradient (personal communications from Holmes).

Since ABr does indeed

possess some glutamine-dependent PRPP ATase activity whereas Ade~PAB has
virtually none, these findings clarify the previously mentioned lack of
complementation between Ade"A and Ade”PAB»

Additionally, PRPP ATase in

Ade“PAB ancl in ABr 1S found to have greatly increased sensitivity to
thermal inactivation (personal communication from Holmes).

Therefore,

these data suggest a structural mutation in PRPP ATase which causes a
severe defect in Ade~PAB and only a moderate change in ABr.
Studies on the growth rate of ABr in various media are consistent
with the altered affinity for glutamine by PRPP ATase.

In purine-free

media, ABr has a slower rate of growth than CHO, with a doubling time of
20.6 hrs versus 12.5 hrs, respectively.

However, in media supplemented
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with hypoxanthine, ABr approaches wild-type growth rates (1).
Additionally, all media contain some added glutamine since CH0-K1 cell
lines are auxotrophic for glutamine.

Supplementation of purine-free

media with 10 times the normal level of glutamine increases the growth
rate of ABr to near normal levels (personal communication from Holmes).
These results imply that the decreased rate of de novo synthesis of
purines in ABr can be accelerated by increasing the concentration of
glutamine.

These growth rate and enzyme activity studies of ABr

indirectly demonstrate the importance of glutamine-dependent PRPP ATase
activity in the rate of de novo purine synthesis.
Accumulation of FGAR and formation of completed purines by wild-type,
purine auxotrophic mutants, and revertant cell lines are direct methods
employed to examine the rate of de novo purine biosynthesis (1).

Oates,

et al incubated cells with ^C-formate in purine-free media supplemented
with either glutamine or ammonia to measure FGAR and completed purine
synthesis.

The results of Oates, et al (1) on formation of completed

purines expressed as cpm/lO^ cells +_ lOOug/ml azaserine (Aza) are:

CH0-K1

Ade“A

Ade"B

Glutamine (Infl)

74,113

<100

<100

1,414

10,582

Gin (ImM) + Aza

1,056

<100

<100

<100

156

32,947

<100

<100

826

17,873

3,502

<100

<100

100

1,240

NH4CI (lOrrM)
NH4CI (lOmM) + Aza

Ade-PAB

ABr

The addition of azaserine, a glutamine analog, inhibited glutaminedependent FGAR ATase activity at much lower concent rations than it
affected glutamine-dependent PRPP ATase activity, as seen in the figures
from Oates, et al presented below (1).
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The results of the studies on FGAR accumulation and completed purine
formation for Ade“A, Ade’B and CHO were as expected for cell lines
possessing deficient PRPP ATase activity, deficient FGAR ATase activity,
and wild-type enzymatic activities, respectively.
FGAR at a constant low rate in
ammonia.

Ade~P/\B

accumulated

the presence of either glutamine or

This is consistent with the absence of FGAR ATase in Ade~PAB.

The rate of FGAR accumulation is reduced at higher concentrations of
azaserine (>100 yg/ml), consistent with inhibition of PRPP ATase activity.
Conversely, in ABr azaserine concentrations that lead to the accumulation
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of FGAR are consistent with the inhibition of FGAR ATase.

The rate of

production of FGAR is decreased in ABr due to decreased PRPP ATase
activity (1).

Therefore, only when FGAR ATase activity is sufficiently

inhibited will FGAR accumulate in ABr.
These in vivo studies represent attempts to determine the significance
of the mutations in Ade"P/\B (and ln ABr) for de novo purine biosynthesis.
The combined results on enzymatic activity, PRPP ATase thermal
inactivation, apparent affinity for glutamine by PRPP ATase, accumulation
of FGAR, and formation of completed purines (1, and personal communication
from Holmes) are suggestive of a single mutational event affecting two
distinct glutamine-utilizing enzymes.

Increased sensitivity to thermal

inactivation is indirect evidence in Ade~P/\B for a structural alteration
in PRPP ATase.

Data on FGAR ATase show a loss of measurable activity in

Ade"P/\B» with a virtually complete recovery of activity in ABr.
The following is a brief summary in tabular form of the findings on
Ade~P/\b and ABr for PRPP ATase and FGAR ATase activities (1, and personal
communication from Holmes).

Enzyme

Property

PRPP ATase

ammonia-dependent activity

Ade"PAB

ABr

+

+

glutamine-dependent activity
apparent glutamine affinity

i

++

thermal stability

FGAR ATase

+
+

ammonia-dependent activity

o

+

glutamine-dependent activity

o

+

apparent glutamine affinity

?

?

thermal stability

?

?
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+ = near wild type level
4- = decreased from wild type level
++ = markedly decreased from wild type level
o = no measurable activity
? = unknown

The research described in this thesis entails the evaluation of FGAR
ATase in ABr for alterations in structure and enzymatic properties.
Specifically, FGAR ATase is examined for sensitivity to thermal
inactivation and for apparent glutamine affinity.

Since Ade~PAB contains

no measurable FGAR ATase enzymatic activity, these studies are performed
on ABr.

Observations by Holmes (personal communication from Holmes) on

the apparent glutamine Km and the thermal inactivation of PRPP ATase in
Ade"PAB indicate that FGAR ATase in ABr might exhibit some alterations
not examined by Oates, et al

(1).

In conjunction with past observations,

the results on FGAR ATase can provide some insight for the genetic basis
responsible for the altered enzymatic profilesof Ade_P/\B and ABr.
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EXPERIMENTAL PROCEDURES

Materials

14C-Glutamine (50mCi/mmole) and 14C-glycine (1.4mCi/mmole) were
obtained from New England Nuclear.

One preparation of chicken liver

acetone powder was obtained from Sigma.

Another preparation was from

chicken liver obtained from Gold Kist, Durham, N.C. and extracted with
acetone as described in Methods of Enzymology (35).
ribose-5-phosphate were obtained from Sigma.

PRPP, ATP and

All other chemicals were of

the highest grade commercially available.
Cel 1 Lines
Wild type CH0-K1 (CHO), Ade~P/\B revertant (ABr20), and azaserineresistant (ASr) cell lines were generously supplied by Dr. David
Patterson.

Characterization and isolation of ABr20 beyond that described

in the introduction can be found in the paper of Oates, Vannais and
Patterson (1).
Cell lines were maintained under sterile conditions with Ham's F-12
medium plus dialyzed fetal calf serum (5%) supplemented with glutamine
and nonessential amino acids.

Fetal calf serum was dialyzed against

lOOOx volume of normal saline for 24 hours three times.
maintained at 37°C under 5% CO2 and added moisture.
medium, pH 7.4, was changed daily.
infection and confluence.

Cultures were

Dialyzed culture

Cultures were checked daily for

Cells were split 1:3 - 1:4 at 2-4 day

intervals when confluent monolayers were observed.

Cultures were kept in

Petri dishes or roller bottles for increased production.

Cells were

split 1-2 days prior to harvesting and were harvested prior to confluence
to insure rapid cell growth rates.

This ensured maximal yield of the

enzymes of the purine de novo biosynthetic pathway.

a
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Enzyme Extraction
Cell-free extracts were prepared as follows.
dissociated with trypsin (1 mg/ml).

Cells were first

Cells were then concentrated by

centrifugation to 2x10^ cells/ml of phosphate buffered saline (containing
the following in mmol/liter; NaCl 137, KC1 2.7, Na2HP04 8.1, KH2PO4 0.62,
dextrose 5.56, and chloroform 3.35).

Cell disruption was by freeze-

thawing three times with a dry ice-acetone bath.

Centrifugation to

remove cellular debris produced a supernatant of an "enzyme extract"
which was then stored in small aliquots at -70°C.

On the day of use

enzyme extract was dialyzed against 1000 volumes of Tris buffer (50nf!
pH=7.4) for 2 hours at 4°C.
Protein concentration for enzyme extracts was determined by the
method of Lowry, et al

(36) modified to correct for the Tris buffer.

Bovine serum albumin was used as a standard.
Preparation of FGAR
Commercial preparations of FGAR are not available.

FGAR was

synthesized using the enzymes of the purine de novo pathway from chicken
liver acetone powder (37).

FGAR ATase activity was blocked with

azaserine as described in Methods of Enzymology (37).

Serial dilutions

of FGAR were used to determine that sufficient FGAR was available to
maintain optimal enzyme activity for 45 minutes in the FGAR ATase
activity assay described below (data not shown).
FGAR ATase Activity Assay
FGAR ATase activity was determined by measuring the FGAR-dependent
conversion of radioactive glutamine to radioactive glutamate.

For each

experimental sample with FGAR present, a control was done with Tris
buffer replacing FGAR.

All assays were performed in duplicate.

mixtures of 50 microliters contained:

Assay

Tris 50mM pH=7.4, MgCl2 lOnfl, KC1

iimuuii
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lOOnti, ATP 10nM, 14C-glutamine 4mM (specific activity 0.42mCi /mmole),
FGAR solution (5 microliters), and dialyzed enzyme extract (25
microliters).

Although FGAR concentration was not known, preliminary

experiments demonstrated that this substrate was not limiting in this
assay.

All solutions were kept at 4°C until incubation at 37°C for 45

minutes unless otherwise specified.

The reaction was stopped by

immersion in an ice-water bath at 4°C.
Electrophoresis on Whatman 3MM paper was promptly carried out.

Ten

microliters of a carrier solution of glutamine (4 mg/ml) and glutamate
(4 mg/ml) was applied and dried prior to applying 15 microliters of assay
mixture.

Electrophoresis in borate buffer (50mM) with 2000 volts at 250

mAmps for 35 minutes was sufficient to separate glutamine and glutamate.
The glutamate spot was identified with ninhydrin spray and cut out.
Radioactivity was counted in a solution of PP0/P0P0P (15.12 gm
2,5-Diphenyloxazole/378 mg P-bis[2-(5-Phenyloxazoyl)]-benzene/8 pints
toluene) for 10 minutes with 60% efficiency.
The assay for FGAR ATase is linear with time (to 60 minutes) and
protein concentration (data not shown).
Oetermination of Apparent Glutamine Affinity of FGAR ATase and
G1utaminase
Glutamine concentrations were varied from 0.167mM to 4mM while all
other assays conditions were held constant.

Measurements without FGAR in

the reaction mixtures were subtracted from each result.
determined the FGAR ATase activity.

This difference

Glutaminase activity is measured by

the conversion of glutamine to glutamate without FGAR present and is
linear with time and protein concentration.
Thermal Inacti vation of FGAR ATase and Glutamine
Following dialysis as described in Enzyme Extraction, the enzyme
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extract was heated to 50°C in a water bath for variable lengths of time.
The enzyme extract for each time point was heated in a single test tube
and then aliquoted for duplicate assays.

Enzyme extract was constantly

kept at 4°C on an ice-water bath while being handled.

Maximal enzyme

activity was measured by maintaining a sample of enzyme extract at 4°C
during the period of inactivation.

Glutaminase activity was determined

in controls without FGAR present.
Sucrose Density Gradient Study
PRPP ATase is known to exist in two forms (15).

In the presence of

PRPP a 133,000 dalton form exists, while in the presence of AMP a 270,000
dal ton form predominates.

In an attempt to determine an association

between PRPP ATase and FGAR ATase, enzyme extracts with either PRPP or
AMP present were applied to sucrose gradients and fractions assayed for
FGAR ATase activity.
Enzyme extract from the ABr cell line was prepared as described in
Enzyme Extraction and used on the same day.

Separate aliquots of the

dialyzed extract were incubated at 37° for 15 minutes with either 5.OrrM
AMP or 0.5mM PRPP.

Each aliquot (200x) was then placed on 11.6 ml of a

sucrose density gradient of 10% to 28.2% with potassium phosphate buffer
(50mM KPi pH=7.4, 15mM S-mercaptoethanol, and 5mM MgCl2) and with either
5.0mM AMP or 0.5mM PRPP.

Centrifugation at 100,000 x g was carried out

for 16 hours in a 1.1 cm diameter tube.

Fractions of 0.2 ml were collected

and enzyme activity measured over a 60 minute incubation period at 37°C
as previously described, except for the use of 32.5x of extract and 17.5x
of reaction mixture.

All reaction concentrations were otherwise

unchanged from that previously described in the FGAR ATase activity
assay.
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RESULTS

Properties of the Enzyme Extract
Table 1 contains data comparing enzyme extracts from CHO and from
ABr.

These data are compiled from multiple experiments, including some

not presented for the thermal inactivation and glutamine affinity
studies.

Overall, the enzyme extracts of ABr minimally differ by 1 to

1.5 standard deviations from the extracts of CHO in average specific
activity and protein concentration.

Protein concentration does vary

significantly (p <0.05); however, the 3 mg/ml
ABr and CHO is not large.

(20%) difference between

Therefore, the actual enzyme extraction

procedure produces equivalent preparations for ABr and CHO.
Thermal Inactivation Studies
Structural changes in enzymes can sometimes be indirectly
demonstrated by an increased sensitivity to thermal degradation (1).
PRPP ATase from ABr is more sensitive to inactivation at 37°C than that
from CHO (personal communication from Holmes).

FGAR ATase is relatively

stable at 37°C (data not shown), but following dialysis it is rapidly
inactivated at 50°C.

The T

1/2

of FGAR ATase activity at 50°C in

dialyzed extracts of ABr is half that of CHO, with decay constants of 0.9
minutes and 1.7 minutes, respectively (Figure 1).
1

The data shown in Fig.

represent the combined results of two thermal inactivation experiments.
For the thermal inactivation studies, when compared to CHO enzyme

extracts, those from ABr have a slightly greater FGAR ATase specific
activity (13.8 nmol/mg protein/hr versus 10.1 nmol/mg protein/hr) and a
slightly greater protein concentration (18.4 mg/ml versus 15.6 mg/ml).
The differences between these parameters for the enzyme preparations of
ABr and CHO are small in comparison to the nearly two-fold alteration in
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the rate of inactivation of FGAR ATase at 50°C.
Additionally, glutaminase from both ABr and CHO decays to 50% of the
original activity in approximately 3 minutes (Figure 2).

Therefore, the

rate of inactivation of glutaminase is essentially the same for ABr and
CHO.

These results on glutaminase demonstrate that under the conditions

of this study ABr possesses an enzymatic activity which is virtually
unaltered in its sensitivity to thermal inactivation.

This is especially

important to note when compared to the results demonstrating a two-fold
difference between ABr and CHO in the thermal inactivation of FGAR ATase
(Figures 1 and 2).
Apparent Affinity for Glutamine
The apparent affinity for glutamine of PRPP ATase is severely
decreased in Ade~P/\g and only moderately affected in ABr (personal
communication from Holmes).

Figure 3 demonstrates

the apparent affinity

for glutamine of FGAR ATase from ABr as being similar to

that from CHO.

The apparent Km for glutamine of ABr and CHO are 0.54mM and 0.86mM,
respectively, with the least-squares plots having correlation
coefficients of at least 0.86.

These results are comparable to that

previously found for the apparent glutamine Km of FGAR ATase from avian
liver, 0.2mM to 0.62mM (27,28) and from Ehrlich ascites tumor cells,
O.llmM (24).

Least-squares analysis of a Michaelis-Menten plot in

Cartesian coordinates for the data in Figure 3 yield large standard
errors for the apparent glutamine Km of FGAR ATase (mean standard error,
T$2

= 0.41).

Therefore, least-squares analysis of the data in the

reciprocal plot (as in Figure 3) is the method employed throughout this
paper.

As demonstrated by the overlap on Figure 3, little difference is

seen in the extrapolated values for the apparent glutamine Km of FGAR
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ATase from ABr and CHO.
The enzyme extracts from ABr and CHO for the study of apparent
glutamine affinity of FGAR ATase possess approximately equal activities,
under assay conditions, 18.1 nmol/mg protein/hr versus 18.6 nmol/mg
protein/hr, respectively.

Extrapolation of the data in Figure 3 yields

FGAR ATase Vmax for ABr and CHO of 22.2 nmol/mg protein/hr and 30.0
nmol/mg protein/hr, respectively.

The slightly lower Vmax of FGAR ATase

from ABr, 74% of the wild-type level, is a small change given the
complete absence of FGAR ATase activity in Ade”PAB»

ABr and CHO enzyme

extracts are also approximately equal in protein concentrations, 11.5
mg/ml and 13.4 mg/ml, respectively.

Therefore, the enzyme extracts do

not greatly differ for these parameters between ABr and CHO in this
study.
As a further control the apparent glutamine affinity of glutaminase
activity in ABr and CHO are virtually equal, 0.25mM and 0.30mM,
respectively (Figure 4).

These least-squares plots also demonstrate a

slightly lower Vmax for ABr in comparison to CHO, 15.8 nmol/mg protein/hr
versus 21.8 nmol/mg protein/hr, respectively.

The high values of the

correlation coefficients for these results (at least 0.95) are due to the
calculation of glutaminase activity from the measurement of one radioac¬
tive sample.

Whereas FGAR ATase activity is the difference between two

samples (one with and one without FGAR), glutaminase activity is only the
result of one sample (without FGAR present).

Therefore, much less

variation is present in the plots for glutaminase (Figure 4) than in the
plots for FGAR ATase (Figure 3).
Additionally, in ABr the slightly greater apparent affinity for
glutamine (lower apparent Km) of glutaminase parallels that of FGAR
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ATase.

This tends to minimize the slight difference in apparent

glutamine affinity of FGAR ATase, since a similar finding is demonstrated
for glutaminase.

Therefore, the result that enzyme extracts from ABr are

equivalent to those from CHO in apparent glutamine affinity of FGAR ATase
can be made with greater certainty.
Other Results
Preliminary studies were performed on a sucrose density gradient for
ABr and on enzyme dilutions for an azaserine-resistant cell line (ASr).
These results are briefly presented below without the actual data.
FGAR ATase retains activity in conditions of a sucrose density
gradient.

When applied to a sucrose density gradient, insufficient FGAR

ATase activity is present to be accurately distinguished from background.
Therefore, the determination of any multienzyme complex with PRPP ATase
is not practical with the crude dialyzed enzyme extract in use.
Isolation of a cell line which overproduces FGAR ATase would have
aided in the sucrose density gradient studies.

Since azaserine is a

potent inhibitor of FGAR ATase, ASr was thought to be a possible
overproducer of FGAR ATase.

ASr cells are resistant to growth inhibition

at lug/ml concentration of azaserine was assayed for FGAR ATase enzyme
activity.

FGAR ATase is inhibited at azaserine concentrations of

0.1 yg/ml or less.

Serial dilutions (1:2, 1:5, 1:10) of enzyme extracts

from ASr and CHO possess comparable activities.
appear to be an overproducer of FGAR ATase.

Therefore, ASr does not
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DISCUSSION

Alterations of PRPP ATase and FGAR ATase in Ade_PAB might be regula¬
tory or structural in their nature®

In Aerobacter aerogenes both PRPP

ATase and FGAR ATase are coordinated repressed and derepressed (38).
However, research has identified structural alterations in both enzymes
for Ade"PAB«

The structural change in PRPP ATase involves the utiliza¬

tion and binding of glutamine.

Glutamine-dependent PRPP ATase in Ade~PAB

has markedly decreased affinity for glutamine while in ABr it is only
moderately decreased (1, personal communication).

Additionally,

increased sensitivity to thermal inactivation of PRPP ATase in Ade_PAB
and ABr, indirectly demonstrating structural alteration, has been found
(personal communication from Holmes).
FGAR ATase activity lost in Ade~PAB is almost completely recovered in
ABr (1).

The results of experiments on FGAR ATase from ABr demonstrate

an increased sensitivity to thermal inactivation (Figure 1).

This is not

unusual in that increased sensitivity to thermal inactivation is found to
be common among revertant cell lines (1).

The most likely explanation

for this increased sensitivity is a structural change(s) in FGAR ATase
from ABr.
Other possible causes of the increased sensitivity to thermal
inactivation involve an altered intracellular environment which offers
less protection to FGAR ATase in crude dialyzed enzyme extracts from ABr.
Diffusible, low molecular weight compounds are removed by dialysis.

This

includes glutamine, potassium, FGAR, magnesium, and ATP which have been
shown to increase the stability of FGAR ATase (23,39).

A non-diffusible

glutamine-enzyme complex for FGAR ATase with increased stability at 50°C
has also been described (23,25,39).

The presence of any glutamine-enzyme
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complex cannot be totally eliminated from having a potential effect upon
the measured rates of thermal inactivation.

However, the studies on FGAR

ATase affinity for glutamine (Figure 3) demonstrate only a minimal
difference between ABr and CHO, with binding constants of 0.54mM and
0.86mM, respectively.

Any protection from a greater amount of

glutamine-enzyme complex in ABr (due to increased glutamine affinity)
would be expected to increase the thermal stability of FGAR ATase.

Since

just the opposite is observed, it is unlikely that a glutamine-enzyme
complex can be responsible for the increased sensitivity to thermal
inactivation of FGAR ATase from ABr.
The decreased thermal stability in ABr (and Ade_PAB) might be due to
altered transport of glutamine.
glutamine.

CH0-K1 cells are auxotrophic for

Then, although the media for CHO and ABr contain the same

concentration of glutamine, the intracellular concentration of glutamine
could be lower in ABr than in CHO.

Lowered intracellular glutamine

concentration might then lead to less protection of FGAR ATase by
decreasing the amount of glutamine-enzyme complex.

This is felt to be

unlikely in that structural changes in PRPP ATase from Ade-P/\B and ABr
have been documented (1, and personal communication from Holmes).
Additionally, loss of measurable FGAR ATase activity in Ade'PAB is
well-established (1).

Therefore, decreased glutamine transport would

involve yet a third alteration in CHO to produce Ade_PAB from a probable
single mutation.
As a further control, glutaminase was examined for thermal sensitivity
and apparent glutamine affinity.

The rate of inactivation of glutaminase

at 50°C is the same for ABr and CHO (Figure 2).

This finding serves to

emphasize the two-fold difference found for the thermal inactivation of
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FGAR ATase between ABr and CHO (Figure 1).

Conversely, the slightly

greater apparent glutamine affinity of glutaminase from ABr (Figure 4)
minimizes the slightly greater apparent glutamine affinity of FGAR ATase
from ABr (Figure 3).

Therefore, the increased thermal inactivation of

FGAR ATase from ABr is indirect proof of some structural alteration, and
most likely is not due to decreased glutamine-enzyme complex from either
decreased apparent glutamine affinity or decreased amounts of
intracellular glutamine.
The evaluation of Ade~PAB as a result of a single mutational event
producing structural changes in two enzymes will be elaborated on later.
It is of

interest to first point out an important conclusion that may be

drawn from the preceding investigations of Oates, et al
Holmes (personal communication).

(1) and E.W.

As mentioned in the Introduction,

Ade-P/\8 retains only measurable ammonia-dependent PRPP ATase activity
(1), while ABr also possesses some measurable glutamine-dependent PRPP
ATase activity.

Additionally, both Ade~PAB and ABr have normal

ribose-5-phosphate ami notransferase which converts ribose-5-phosphate and
ammonia to phosphoribosylamine (PRA) (1).

However, in complementation of

Ade"PAR an^ Ade"A (with normal FGAR ATase activity), neither
ammonia-dependent PRPP ATase nor ribose-5-phosphate aminotransferase form
sufficient PRA in vivo to sustain cellular function.

Therefore, in this

mammalian system the de novo synthesis of purines requires
glutamine-dependent PRPP ATase activity.

This conclusion is further

supported by finding that increased concentrations of glutamine raises
the growth rate of ABr to wild-type levels (CH0-K1 is a glutamine
auxotroph), thereby overcoming the decreased apparent affinity for
glutamine by PRPP ATase in ABr (personal communication from Holmes).
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It should also be mentioned that Ade~PAB represents a separation of
glutamine and ammonia-dependent PRPP ATase activities.

Glutamine-

dependent activity is virtually lost in Ade"PAB due to a marked decrease
in apparent affinity for glutamine (personal communication), while
ammonia-dependent activity is almost normal

(1).

There are some reports

of separating these enzymatic activities in partially purified
preparations (40).

However, single mutational events were clearly shown

to form cell lines deficient in both glutamine and ammonia-dependent PRPP
ATase (30,31,33).

Additionally, purified human PRPP ATase has recently

been found to maintain a constant ratio of glutamine-dependent to
ammonia-dependent activities (14).

Therefore, the enzyme alterations in

Ade_PAB which keep the ammonia-dependent PRPP ATase activity basically
intact and markedly decreases the apparent glutamine affinity of
(glutamine-dependent) PRPP ATase activity

imply a more complicated

explanation than if both activities were simultaneously altered.
Before presenting various explanations to account for the enzymatic
character!'stics of Ade"PAB» I will briefly summarize some of the relevant
information.

Both PRPP ATase deficient cell lines (Ade“A) and FGAR ATase

deficient cell lines (Ade~B) have been isolated (29-31,33,41,42).

Both

PRPP ATase and FGAR ATase have been purified as separate and distinct
enzymes (14,22,23).

Human PRPP ATase has been purified and is composed

of 4-5 homogeneous subunits with molecular weights of 30,000 each (14).
FGAR ATase from chicken liver is composed of a single polypeptide with a
molecular weight of 133,000 (23).

The existence of the Ade_PAB cell line

with structurally altered PRPP ATase and FGAR ATase from a probably
single mutational event is an interesting occurrence.

Evidence for a

single mutation producing Ade-PAB is based upon isolation technique.
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isolation frequency, and reversion frequency.

Evidence for the enzymatic

profile of Ade-PAB as the result of structural changes in both PRPP ATase
and FGAR ATase is as follows.

Ade-P/\B possesses almost normal

ammonia-dependent PRPP ATase, markedly altered apparent glutamine
affinity of (glutamine-dependent) PRPP ATase and loss of FGAR ATase.
Similarly, ARr possesses almost normal ammonia-dependent PRPP ATase,
moderately altered apparent glutamine affinity of (glutamine-dependent)
PRPP ATase and virtually normal FGAR ATase (1, personal communication
from Holmes).

Also, increased sensitivities to thermal inactivation

indirectly demonstrate structural alterations in PRPP ATase and FGAR
ATase from Ade’PAB and ABr.

Experiments on the glutamine affinity of

FGAR ATase from ABr demonstrate no difference between ABr and CHO.
Therefore, I postulate that some structural alteration of FGAR ATase in
Ade"P/\B

results in an enzyme which is catalyti cal ly inactive and/or

extremely labile, but this mutation need not affect glutamine binding.
Addition of the data presented in this thesis to the tabular summary
present in the Introduction on the findings for Ade"P,AB and ABr yields:

Enzyme

Property

PRPP ATase

FGAR ATase

Ade"PAB

ABr

ammonia-dependent activity

+

+

glutamine-dependent activity

4'

4-

apparent glutamine affinity

4' 4-

4-

thermal stability

4-4-

+

ammonia-dependent activity

0

+

glutamine-dependent activity

0

+

apparent glutamine affinity

(+)

thermal stability

(+)
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+ = near wild type level
4- = decreased from wild type level
+4- = markedly decreased from wild type level
o = no measurable activity
* = result presented in this thesis
( ) = postulated from results presented

Possible explanations for the existence of Ade~P/\B roust also take
into account that Ade"PAB does not complement Ade'A, Ade"B nor itself,
but does complement all other purine auxotrophs (Ade"C, Ade"D, Ade"E...)
(1).

Additionally, coincubation of crude extracts of Ade"PAB» Ade"A,

Ade"B, and CHO in mixing studies does not result in any alteration of
PRPP ATase or FGAR ATase activities (1).

Since normal enzymatic

activities are possible in the presence of Ade"PAB

extract, any theory

involving modification of PRPP ATase and FGAR ATase in the cytosol is
unlikely.

This precludes the presence of a diffusible inhibitory

substance.

In complementation studies, a normal post-translational

modification would be expected to modify enzyme from both cell lines;
however, an inability to complement Ade_A and Ade_B demonstrates that such
is not the case for Ade~PAB

(1).

Since FGAR ATase retains little

enzymatic activity when blocked with the glutamine analog azaserine, a
diffusible inhibitory substance present in Ade~PAB

that could affect

both glutamine-dependent PRPP ATase and FGAR ATase might be a glutamine
analog.

However, mixing studies of extracts from Ade“PAB tail to inhibit

PRPP ATase and FGAR ATase from other cell lines (1).

Therefore, like

alterations in post-translational modification, the presence of a
diffusible inhibitory substance is doubtful.
If the alterations in PRPP ATase and FGAR ATase in Ade_PAB are not
inherent in the cytosol, then the two enzymes may have effects upon each
other in the cytosol.

For example, the existence of multienzyme
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complexes is a possibility.

A multienzyme complex would seem favorable

since many of the intermediates of the de novo purine biosynthetic
pathway are unstable (43).

Early reports on the characteristics of the

enzymes involved revealed some partial co-purification (44).

However,

further research demonstrated that these enzymes are not present in a
tight multienzyme complex (45).
If PRPP ATase and FGAR ATase do not affect each other in a
multienzyme complex, then perhaps they share a common subunit which when
altered could affect both enzymes.

It has been postulated that some of

the glutamine-utilizing ami dotransferases are the union of separate
glutaminase and ammonia-utilizing aminotransferase polypeptides (27).
Glutaminase activity would reside on a separate polypeptide, with
enzymatic specificity conferred by the individual ami notransferase
polypeptide.

Such a mechanism seems unlikely in that PRPP ATase is

formed of 4-5 homogeneous subunits with a molecular weight of 30,000 (14)
and FGAR ATase is a single polypeptide with a molecular weight of
133,000 (23).

Although PRPP ATase and FGAR ATase are from different

species (human and avian sources, respectively), subunits of PRPP ATase
are also found in bacteria (22,46,50).

Additionally, no distinct

glutaminase activity has been separated from purified preparations of
either PRPP ATase or FGAR ATase (14,22,23,46).

Therefore, it seems

doubtful that PRPP ATase and FGAR ATase share some common subunit,
especially when one considers that PRPP ATase is separable into 4-5
homogeneous subunits and FGAR ATase is a single polypeptide.
Postulating the theoretical existence of a single multifunctional
polypeptide could explain many of the mutational findings for Ade-Pftg.
Such a polypeptide is not without precedent, in that a multifunctional
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polypeptide has been identified which catalyzes the first three reactions
of the de novo pyrimidine biosynthetic pathway (47-49).
polypeptide is consistent with the production of Ade“P/\g

A multifunctional
by a single

mutational event which then alters more than one enzyme activity.

The

mixing studies, the complementation pattern of Ade"PAB> and the not
uncommon formation of revertants are in agreement with such a theoretical
multifunctional polypeptide.
Additionally, coordinate control in the production of PRPP ATase and

FGAR ATase has been demonstrated for bacteria (37).

This type of

regulation of the level of enzymes of a pathway has been described for
the (previously mentioned) first three enzymes of the de novo pyrimidine
biosynthetic pathway (47,48) and for two non-sequential enzymes of the de
novo purine biosynthetic pathway (49).

The identification of a

multifunctional protein catalyzing the first three reactions of the de
novo pyrimidine biosynthetic pathway explains the findings for these
enzymatic activities.

The two non-sequential enzymes of the de novo

purine biosynthesis are the third and the sixth enzymes of the pathway,
phosphoribosylglycinamide synthetase (GAR synthetase, EC 6.3.4.13) and
phosphoribosylaminoimidazole synthetase (AIR synthetase, EC 6.3.3.1),
respectively.

Both GAR synthetase and AIR synthetase have been assigned

to chromosome 21.

Also, a purine auxotrophic cell line (Ade~PcG) and its

revertants have been reported which first lost and then regained both GAR
synthetase and AIR synthetase (49).

Therefore, the coordinate regulation

of GAR Synthetase and AIR Synthetase may be under the direction of a
single regulatory unit which is mutated in Ade~PcG and its revertants.
However, for Ade'PAB The structural changes in both PRPP ATase and FGAR
ATase cannot be easily explained by mutation in a similar regulatory unit.
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None of the possible explanations presented above satisfactorily deals
with all of the enzymatic and genetic characteristics of Ade“PAB (anc*
ABr).

A theoretical multifunctional polypeptide can explain the

structural alteration of two enzymes from one mutational event.

However,

the purification of separate and distinct enzymes makes this theory
unlikely.

Additionally, the complementation pattern of Ade"A and Ade'B

point to two separate genes for these enzymes.

The separate

complementation group Ade_PAB could be explained by its affecting a
multienzyme complex.

Such a complex is demonstrated for the last two

enzymes of the purine de novo biosynthetic pathway leading to formation
of IMP (phosphoribosyl-aminoimidazolecarboxamide transformylase, EC
2.1.2.3 and inosine-5'-monophosphate cyclohydrolase, EC 3.5.4.10;
reference 51).

Additionally, in Salmonella typhimurium, identification

of a third complementation group (distinct from the two groups for each
enzyme) has been shown to affect the interaction between these two
enzymes (52).

This is demonstrated by the restoration of low

transformylase activity from this third complementation group by the
addition of normal cyclohydrolase.

However, a similar mixing study for

PRPP ATase and FGAR ATase from Ade'PAB
activities (1).

does not affect any enzyme

Therefore, PRPP ATase and FGAR ATase are probably not in

a tight multienzyme complex similar to that of transformylase and
cyclohydrolase.
Ade~PAB is a third complementation group to Ade~A and Ade_B«
Therefore, it appears to involve a third gene distinct from the two genes
coding for PRPP ATase and FGAR ATase.

A model for Ade“PAB might involve

the theoretical existence of a single precursor for PRPP ATase and FGAR
ATase.

Given the complexities of mammalian systems, such a precursor
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could exist at the DNA, RNA or polypeptide level.

Ade~P/\3 would then be

the result of a mutation in the separation of the PRPP ATase and FGAR
ATase segments at one of these three levels.
The marked decrease in apparent glutamine affinity of
(glutamine-dependent) PRPP ATase in Ade~PAB with reversion to a moderate
decrease in ABr could be explained by the following hypothesis.

The

Y-glutamyl intermediate formed during glutamine hydrolysis has recently
been shown to bind to the N-terminal cysteine residue on PRPP ATase in E.
coli

(53).

If one assumes that the FGAR ATase gene is located "proximal"

or on the 5'-end of the PRPP ATase gene, a mutation could lead to an
error in the splicing of DNA or RNA or in the separation of these two
enzymes such that the glutamine site of PRPP ATase (at its N-terminal
end) and a crucial enzymatic site of FGAR ATase (at its C-terminal end)
would both be affected.
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Since the active cysteine residue is normally a N-terminal residue,
then the presence of several extra amino acids in Ade"PAB might
severely disrupt the glutamine-utilizing section of PRPP ATase and only
minimally affect the ammonia-utilizing section of PRPP ATase.

FGAR ATase

activity would be simultaneously lost due to a mutation in the C-terminal
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portion of this protein.

For reversion to take place, the position for

DNA or RNA splicing or for separation of two polypeptides would change to
a position which added at least one (but not too many) amino acids to the
N-terminus of PRPP ATase in ABr.

The altered glutamine binding of PRPP

ATase would then be less marked.

Also, FGAR ATase could be almost fully

active, and might only exhibit the loss of some non-functional amino
acids with a decrease in thermal stability.
The presumed change in the position of the separation between PRPP
ATase and FGAR ATase would of necessity be due to alterations in the
genetic code.

There is little information to speculate even further on

the nature or mechanism of the putative defect in the splicing process.
However, the model presented does fit all of the known properties of
Ade“P/\B and ABr.
The complementation properties of Ade"PAB and ABr are in accord with
this model; however, the recent mapping of PRPP ATase and FGAR ATase to
different human chromosomes does cast doubt on this model.
has been tentatively assigned to human chromosome 4 (54).

PRPP ATase
FGAR ATase was

initially localized to human chromosome 4 by linkage to esterase
production (55), but has been reassigned to human chromosome 14 (56).
Although the genome of the Chinese hamster cell may differ from human
cells with regard to the chromosomal localization of PRPP ATase and FGAR
ATase, the model proposed above for Ade"P/\g

is not supported by the

finding for human cells.
Short of isolating and sequencing PRPP ATase and FGAR ATase from
Ade-P/\B and ABr, a simpler experimental method involves examination of
the N-terminus of PRPP ATase.

If PRPP ATase from Chinese hamster ovary

cells possess the same N-terminal, glutamine binding cysteine residue as
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found for E. Coli

(53), then this could be identified by first

irreversibly binding a radiolabelled glutamine analog such as azaserine
or DON (6-diazo-5-oxo-L-norleucine).

Next, a single step of Edman

degradation could be performed to determine if a radioactive glutamine
analog-cysteine unit was the N-terminal residue.

If the alterations

which formed Ade_P/\B and ABr produced extra N-terminal amino acids on
PRPP ATase, then both cell lines would demonstrate an absence of tfre
radioactive glutamine analog-cysteine residue.
consistent with the model presented above.

This finding would be
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TABLE 1

FGAR ATase Specific Activity and Protein Concentration

Means and standard deviations are compilations of multiple
experiments with ABr and CHO enzyme extracts.

Values are expressed as

mean +_ standard deviation (sample size).

ABr

CHO

FGAR ATase Specific Activity*
(nmol/mg protein/hr)

13.8 _+ 3.55 (10)

14.5^3.80 (11)

Protein Concentration
(mg/ml)

12.5 +_ 3.35 (11)

15.3 +_ 1.86 (12)

*Activity is measured at 4mM glutamine.
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Thermal Inactivation of FGAR ATase:

ABr (o) and CHO (») are each the

averaged result of two separate experiments.

Dialyzed enzyme extracts

from ABr and CHO are simultaneously heated to 50°C in open glass test
tubes for 0.25 minutes to 4 minutes and immediately placed on an icewater bath.

Interpolation of the data yields the time required for the

loss of 50% of FGAR ATase activity for ABr as 0.9 minutes and for CHO as
1.7 minutes.
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Thermal Inactivation of Glutaminase:

ABr (o) and CHO (•) are each the

combination of three separate experiments.

All points are compiled from two

independent studies except at 0.5, 1, and 3 minutes, which are each from one
study.

Dialyzed enzyme extract is heated to 50°C in an open glass test tube

for 0.5 minutes to 10 minutes and then immediately placed on an ice-water
bath.

Results are drawn from the control data which are the reaction

mixtures without FGAR present.
curve of the other data points.

The 3 minute point does not lie on a smooth
Since it is also from one experiment and

not as reliable, it is left out of the curve.

By interpolation, both ABr

and CHO lose 50% of their glutaminase activities in approximately 3 minutes.
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Apparent Glutamine Affinity of FGAR ATase:

Reciprocal plot of FGAR ATase

specific activity and glutamine concentration.

ABr (o) is the result of

three experiments and CHO (o) is the result of two experiments.

Glutamine

concentrations vary while all other enzyme assay conditions remain
constant.

Glutamine concentrations greater than ImM approach saturation

and are therefore not in these plots.

A least-squares plot for ABr yields

an apparent glutamine Km of 0.54mM and a Vmax of 22.2 nmol/mg
protein/hr, with a correlation coefficient of 0.86.

Similar analysis for

CHO produce an apparent glutamine Km of 0.86mM and Vmax of 33.0 nmol/mg
protein/hr, with a correlation coefficient of 0.90.

37

Apparent Glutamine Affinity of Glutaminase:

ABr (o) is the result of

three experiments and CHO («) is the result of two experiments.

These

results are extracted from the controls of the glutamine binding study
which are enzyme assays without FGAR.

A least-squares plot for ABr yields

an apparent glutamine Km of 0.25mM and Vmax 15.8 nmol/mg protein/hr, with
a correlation coefficient of 0.98.

The results for CHO are an apparent

glutamine Km of 0.30mM and Vmax of 21.8 nmol/mg protein/hr, with a
correlation coefficient of 0.95.

38

FOOTNOTES

1.

Oates, D.C., Vannais, 0., Patterson, D. A mutant of CHQ-K1 cells
deficient in two nonsequential steps of de novo purine biosynthesis.
Cell, Vol. 20, 797-805, July 1980.

2.

Holmes, E.W.
In Handbook of Experimental Pharmacology, edited by
Kelley, W.N. and Weiner, I.M. Published by Springer-Verlag, Berlin,
Heidelberg, 1978.

3.

Itakura, M., Sabina, R.L., Heald, P.W., Holmes, E.W. Basis for the
control of purine biosynthesis by purine ribonucleotides. J_. Clin.
Invest. 67;
994-1002, April, 1981.

4.

Taylor, M.W., Olivelle, S., Levine, R.A., Cog, K., Hershey, H.,
Gusta, K.C., Zawistowich, L. Regulation of de novo purine
biosynthesis in Chinese hamster cells. J_. Biol. Chem. 257: #1,
377-380, January 10, 1982.

5.

Welch, M.M., Rudolph, F.B. Regulation of purine biosynthesis and
interconversion in the chick. J. Biol. Chem. 257, #22, 13253-13256,
November 25, 1982.

6.

Rosiers, C. des, Lalanne, M., Willemot, J. Effect of glycerol and
fructose on purine synthesis de novo and on PP-ribose-P availability
in rat liver cells. Can. Jo.HTjochem. 60: 1109-1115, 1982.

7.

Bernlohr, D.A., Switzer, R.L. Reaction of Baci11 us subtilis
glutamine phosphoribosylpyrophosphate amidotransferase with oxygen:
Chemistry and regulation by ligands. Biochem. 20: #20, 5675-5681,
1981.

8.

Ruppen, M.E., Switzer, R.L. Degradation of Baci1lus subti1is
glutamine phosphoribosylpyrophosphate ami dotransferase in vivo.
J. Biol. Chem. 258: #5, 2843-2851, March 10, 1983.

9. Bernlohr, D.A. and Switzer, R.L. Regulation of Baci1lus subti1is
glutamine phosphoribosylpyrophosphate amidotransferase inactivation
in vivo. J_. Bacteri ol. 153: #2, 937-949, February, 1983.
10.

Itakura, M., Holmes, E.W. Regulation of
amidophosphoribosyltransferase activity in Eukaryotic cells by
oxygen inactivation, (in press), personal communication.

11.

Holmes, E.W., McDonald, J.A., McCord, J.M., Wyngaarden, J.M.,
Kelley, W.N.
Human glutamine phosphoribosylpyrophosphate
ami dotransferase: Kinetic and regulatory properties. J_. Biol. Chem.
248: #1 , 144-150, January 10, 1973.

.

12

Kovarsky, J., Evans, M.C., and Holmes, E.W. Regulation of human
amidophosphoribosyltransferase: Interaction of orthophosphate,
PP-ribose-P, and purine ribonucleotides. Can. Jo. Biochem. 56: #5,
334-338, 1978.

39

13.

Meyer, E. and Switzer, R.L. Regulation of Bacillus subtilis
glutamine phosphoribosylpyrophosphate ami dotransferase activity by
end products. J_. Biol. Chem. 254: #6, 5397-5402, June 25, 1979.

14.

Leff, R.L., Itakura, M., Udom, A., and Holmes, E.W.
Amidophosphoribosy1 transferase: A possible role for oxygen
inactivation in the regulation of amidophosphoribosyltransferase
activity in mammalian cells. Advances in Enzyme Regulation 22:
403-411, 1984.

15.

Holmes, E.W., Wyngaarden, J.B., and Kelley, W.N. Human glutamine
phosphoribosylpyrophosphate amidotransferase: Two molecular forms
i nterconvertible by purine ribonucleotides and phosphori bosyIpyrophosphate. J_. Biol. Chem. 248: #17, 6035-6040, September 10, 1973.

16.

Singer, S.C. and Holmes, E.W. Human glutamine phosphoribosylpyrophosphate ami dotransferase: Hysteretic properties. J. Biol. Chem.
252: #22, 7959-7963, November 25, 1977.
“

17.

King, G.L., Bounous, C.G. and Holmes, E.W. Human placental amidophosphoribosyltransferase: Comparison of the kinetics of glutamine
and ammonia utilization. J. Biol. Chem. 253: #11, 3933-3938, June
10, 1978.

18.

Itakura, M. and Holmes, E.W. Human amidophosphoribosyltransferase:
An oxygen-sensitive iron-sulfur protein. J_. Biol. Chem. 254: #2,
333-338, January 25, 1979.

19.

Wong, J.Y., Meyer, E., and Switzer, R.L. Glutamine phosphoribosy1 pyrophosphate amidotransferase from Bacillus subtilis: A novel
iron-sulfur protein. J. Biol. Chem. 252: #2 7424-7426, November 10,
1977.

20.

Averill, B.A., Owivedi, A., Debrunner, P., Vollmer, S.J., Wong,
J.Y., and Switzer, R.L. Evidence for a tetranuclear iron-sulfur
center in glutamine phosphoribosylpyrophosphate amidotransferase
from Bacillus subtilis. J. Biol. Chem. 255: #13, 6007-6010, July
10, 1980.

21.

Vollmer, S.J., Switzer, R.L., Hermodson, M.A., Bower, S.G. and
Zalkin, H. The glutamine-utilizing site of Bacillus subtilis
glutamine phosphoribosylpyrophosphate ami dotransferase. J. Biol.
Chem. 258: #17, 10582-10585, September 10, 1983.

22.

Messenger, L.J. and Zalkin, H. Glutamine phosphoribosylpyrophosphate amidotransferase from Escherichia coli: Purification and
properties. J_. Biol. Chem. 254: #9, 3382-3392, May 10, 1979.

23.

Mizobucki, K. and Buchanan, J.M. Purification and properties of
formyl glyci nami de ribonucleotide ami dotransferase from chicken
liver. J_. Biol. Chem. 243: #18, 4842-4852, September 25, 1968.

40

24.

Chu, S.Y. and Henderson, J.F. Kinetic studies of phosphoribosy1 formylglycineamide synthetase. Can. Jo. Biochem. 50:
490-500,
1972.

25.

Mizobuchi, K. and Buchanan, J.M.
Isolation and character!'zation of
formyl glyci nami de ribonucleotide ami dotransferase-glutamyl complex.
J. Biol. Chem. 243: #18, 4853-4862, September 25, 1968.

26. Mizobuchi, K., Kenyon, G.L. and Buchanan, J.M. Binding of
formyl glyci nami de ribonucleotide and adenosine triphosphate to
formyl glyci nami de ribonucleotide ami dotransferase. J_. Biol. Chem.
243: #18, 4863-4877, September 25, 1968.
27.

Li, H.C. and Buchanan, J.M. Catalytic properties of the glutamine
site of formyl glyci nami de ribonucleotide ami dot ransferase from
chicken liver. J. Biol. Chem. 246: #15, 4713-4719, August 10,
1971.

28.

Levenberg, B., Melmick, I., Buchanan, J.M. The effect of Aza-Lserine and 6-diazo-5-oxo-L-norleucine on inosine acid biosynthesis
de novo. J. Biol. Chem. 255: #1, 163-176, March, 1957.

29.

Patterson, 0., Kao, F.T. and Puck, T.T. Genetics of somatic mutant
cells:
Biochemical genetics of Chinese hamster cell mutants with
deviant purine metabolism. Proc. Nat. Acad. Sci. USA 71: 2057-2061,
1974.

30.

Patterson, D. Biochemical genetics of Chinese hamster cell mutants
with deviant purine metabolism: Biochemical analysis of eight
mutants. Somatic Cel 1 Genet. 1_: 91-1 10, 1975.

31.

Oates, D.C. and Patterson, 0. Biochemical genetics of Chinese
hamster cell mutants with deviant purine metabolism: Characterization
of Chinese hamster cell mutants defective in phosphoribosylpyrophosphate amidotransferase and phosphoribosy1glycinami de synthetase
and an examination of alternatives to the first step of purine
biosynthesis. Somatic Cel 1 Genet. 3_: 561 -577, 1977.

32.

Irwin, M., Oates, D.C. and Patterson. D. Biochemical genetics of
Chinese hamster cell mutants with deviant purine metabolism.
Isolation and characterization of a mutant deficient in the activity
of phosphoribosylaminoimidazole synthetase (E.C. 6.3.3.1). Somatic
Cell Genet. 5_: 203-216, 1979.

33.

Holmes, E.W., King, G.L., Leyva, A. and Singer, S.C. A purine
auxotroph deficient in phosphoribosylpyrophosphate amidotransferase
and phosphoribosyIpyrophosphate ami dotransferase activities with
normal activity of ribose-5-phosphate aminotransferase. Proc. Natl.
Acad. Sci. USA 70: 2458-2461, 1976.
"

34. Kao, F.T. and Puck, T.T. Genetics of somatic mammalian cells. VII.
Induction and isolation of nutritional mutants in Chinese hamster
cells. Proc. Nat. Acad. Sci. USA 60: 1275-1281, 1968.

41

35.

Methods in Enzymology II [78] pp. 508-509.

36.

Lowry, O.H., Rosebrough, N.J., Farr, A.L., Randall, R.S. Protein
measurement with the Folin phenol reagent. J. Biol. Chem. 193:
265-275, 1951.

37.

Methods in Enzymology VI [96] pp. 678-681.

38.

Nierlich, D.P., Magasanik, B. Control by feedback repression of the
enzymes of purine biosynthesis in Aerobacter aerogenes. Biochim. et
Biophys. Acta 230: 342-348, 1971.

39.

Chu, S.Y., Henderson, J.F. Purification and properties of phosphoribosyl-formylglycinamide synthetase of Ehrlich ascites tumor cells.
Can. J. Biochem. 50: 484-489, 1972.

40. Reem, G.H. Enzymatic synthesis of phosphoribosylamine in human
cells. J. Biol. Chem. 249: #6, 1696-1703, March 25, 1974.
41.

Patterson, D., Kao, F.T., Puck, T.T. Genetics of somatic mammalian
cells:
Biochemical genetics of Chinese hamster cell mutants with
deviant purine metabolism. Proc. Natl. Acad. Sci. USA 71: #5,
2057-2061, May, 1974.

42.

Oates, D.C., Patterson, D. Biochemical genetics of Chinese hamster
cell mutants with deviant purine metabolism: Characterization of
Chinese hamster cell mutants defective in phosphoribosylpyrophos¬
phate amidotransferase and phosphoribosylglycinami de synthetase and
an examination of alternatives to the first step of purine
biosynthesis. Somatic Cell Genetics 3: #6, 561-577, 1977.

43.

Wyngaarden, J.B., Appel, S.H., Rowe, P.B. in Exploitable Molecular
Mechanisms and Neoplasia, pp. 415-434, Williams and Wilkins Co.,
Baltimore, 1968.

44.

Rowe, P.B., McCairns, E., Madsen, G., Sauer, D., and Elliott, H. De
novo purine synthesis in Avian liver: Co-purification of the enzymes
and properties of the pathway. J_. Biol. Chem. 253:
#21 , 771 1 -7721 ,
November 10, 1978.

45.

McCairns, E., Fahey, D., Sauer, D., and Rowe, P.B. De novo purine
synthesis in human lymphocytes: Partial co-purification of the
enzymes and some properties of the pathway. J. Biol. Chem. 258: #3,
1851-1856, February 10, 1983.

46.

Wong, J.Y., Bernlohr, D.A., Turnbough, C.L., and Switzer, R.L.
Purification and properties of glutamine phosphoribosylpyrophosphate
amidotransferase from Bacillus subtilis. Biochem. 20: 5669-5674,
1981.

.

47

Coleman, P.F., Suttle, D.P., and Stark, G.R. Purification from
hamster cells of the multifunctional protein that initiates de novo
synthesis of pyrimidine nucleotides. J_. Biol. Chem. 252: #TS7
6379-6385, September 25, 1977.

42

48.

Padgett, R.A., Wahl, G.M., Coleman, P.F., and Stark, G.R. N-(Phosphonacetyl)-L-aspartate-resistant hamster cells overaccumulate a
single mRNA coding for the multifunctional protein that catalyzed
the first steps of UMP synthesis. J_. Biol. Chem. 254: #3, 974-980,
February 10, 1979.

49.

Davidson, J.N. and Patterson, D. Alteration in structure of multi¬
functional protein from Chinese hamster ovary cells defective in
pyrimidine biosynthesis. Proc. Natl. Acad. Sci. USA 76: #4,
1731-1735, April, 1979.

50.

Patterson, D., Graw, S., and Jones, C. Demonstration by somatic
cell genetics of coordinate regulation of genes for two enzymes of
purine synthesis assigned to human chromosome 21. Proc. Natl. Acad.
Sci. USA 78: 405-409, January, 1981.

51. Flaks, J.G., Erwin, M.J., and Buchanan, J.M.
5-Amino-l-ribosy1-4imidazolecarboxamide 5'-phosphate transformylase and inosinicase.
J. Biol. Chem. 229: 603-612, 1957.
52.

Gots, J.S., Dalai, F.R., and Shumas, S.R. Genetic separation of the
inosine acid cyclohydrolase-transformylase complex of Salmonella
typhimurium. J_. Bacteriol. 99: #2, 441-449, August, 196T9~.

53.

Tso, J.Y., Hermodson, M.A., and Zalkin, H. Glutamine phosphoribosy1 pyrophosphate ami dotransferase from cloned Escherichia coli pur F.
J_. Biol. Chem. 257: #7, 3532-3536, April 10, 1982. ~~

54.

Chu, E.H.Y. and Stanley, W. Assignment of the gene for phosphoribosylpyrophosphate amidotransferase to the pter * q21 region of human
chromosome 4. Cytogenet. Cell Genet. 22: 228-231, 1978.

55.

Kao, F.T. and Puck, T.T. Genetics of somatic mammalian cells:
Demonstration of a human esterase activator gene linked to the AdeB
gene. Proc. Natl. Acad. Sci. USA 69: #11, 3273-3277, November,
1972.

56.

Kao, F.T. Chromosomal assignment of the gene for phosphoribosy1 formylglycinamidine synthetase (PFGS) to human chromosome 14.
J_. Cell Biology 87:
Abstracts 291a, November, 1980.

Personal communications are from Holmes, E.W.

YALE MEDICAL LIBRARY
Manuscript Theses

Unpublished theses submitted for the Master's and Doctor's degrees and
deposited in the Yale Medical Library are to be used only with due regard to the
rights of the authors.
Bibliographical references may be noted, but passages
must not be copied without permission of the authors, and without proper credit
being given in subsequent written or published work.

This thesis by
has been
used by the following persons, whose signatures attest their acceptance of the
above restrictions.

NAME AND ADDRESS

DATE

